A detailed history of Massachusetts Financial Services CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Massachusetts Financial Services CO holds 163,054 shares of NBIX stock, worth $20.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
163,054
Previous 155,985 4.53%
Holding current value
$20.1 Million
Previous $21.5 Million 12.58%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$114.58 - $153.15 $809,966 - $1.08 Million
7,069 Added 4.53%
163,054 $18.8 Million
Q2 2024

Aug 09, 2024

BUY
$130.86 - $143.19 $538,096 - $588,797
4,112 Added 2.71%
155,985 $21.5 Million
Q1 2024

May 14, 2024

SELL
$130.4 - $143.74 $3.12 Million - $3.44 Million
-23,904 Reduced 13.6%
151,873 $20.9 Million
Q4 2023

Feb 08, 2024

SELL
$106.07 - $132.76 $14,107 - $17,657
-133 Reduced 0.08%
175,777 $23.2 Million
Q3 2023

Nov 08, 2023

SELL
$94.02 - $117.1 $4,606 - $5,737
-49 Reduced 0.03%
175,910 $19.8 Million
Q2 2023

Aug 09, 2023

BUY
$89.53 - $104.87 $688,933 - $806,974
7,695 Added 4.57%
175,959 $16.6 Million
Q1 2023

May 10, 2023

SELL
$94.11 - $123.02 $1.2 Million - $1.57 Million
-12,751 Reduced 7.04%
168,264 $17 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $61,257 - $72,932
574 Added 0.32%
181,015 $21.6 Million
Q3 2022

Nov 09, 2022

SELL
$92.03 - $107.81 $3.23 Million - $3.78 Million
-35,094 Reduced 16.28%
180,441 $19.2 Million
Q2 2022

Aug 09, 2022

SELL
$75.79 - $100.07 $118,535 - $156,509
-1,564 Reduced 0.72%
215,535 $21 Million
Q1 2022

May 11, 2022

BUY
$72.45 - $94.81 $431,802 - $565,067
5,960 Added 2.82%
217,099 $20.4 Million
Q4 2021

Feb 10, 2022

BUY
$79.65 - $106.22 $2.36 Million - $3.15 Million
29,646 Added 16.33%
211,139 $18 Million
Q3 2021

Nov 10, 2021

BUY
$86.18 - $99.03 $3.29 Million - $3.78 Million
38,165 Added 26.63%
181,493 $17.4 Million
Q2 2021

Aug 13, 2021

SELL
$89.43 - $102.27 $37,471 - $42,851
-419 Reduced 0.29%
143,328 $13.9 Million
Q1 2021

May 13, 2021

SELL
$87.57 - $119.4 $295,373 - $402,736
-3,373 Reduced 2.29%
143,747 $14 Million
Q4 2020

Feb 12, 2021

BUY
$86.91 - $108.33 $2.94 Million - $3.66 Million
33,785 Added 29.81%
147,120 $14.1 Million
Q3 2020

Nov 12, 2020

SELL
$96.16 - $135.15 $263,670 - $370,581
-2,742 Reduced 2.36%
113,335 $10.9 Million
Q2 2020

Aug 11, 2020

SELL
$85.09 - $130.36 $1.12 Million - $1.72 Million
-13,205 Reduced 10.21%
116,077 $14.2 Million
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $221,123 - $334,909
-2,944 Reduced 2.23%
129,282 $11.2 Million
Q4 2019

Feb 13, 2020

BUY
$86.8 - $118.57 $3,558 - $4,861
41 Added 0.03%
132,226 $14.2 Million
Q3 2019

Nov 05, 2019

SELL
$83.82 - $101.5 $41,490 - $50,242
-495 Reduced 0.37%
132,185 $11.9 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $801,575 - $1.01 Million
11,096 Added 9.13%
132,680 $11.2 Million
Q1 2019

May 13, 2019

BUY
$69.31 - $91.53 $1.38 Million - $1.82 Million
19,926 Added 19.6%
121,584 $10.7 Million
Q4 2018

Feb 08, 2019

BUY
$68.32 - $124.36 $767,848 - $1.4 Million
11,239 Added 12.43%
101,658 $7.26 Million
Q3 2018

Oct 25, 2018

SELL
$98.88 - $125.85 $437,840 - $557,263
-4,428 Reduced 4.67%
90,419 $11.1 Million
Q2 2018

Jul 30, 2018

SELL
$75.3 - $105.99 $1.93 Million - $2.72 Million
-25,657 Reduced 21.29%
94,847 $9.32 Million
Q1 2018

May 04, 2018

BUY
$75.88 - $92.43 $900,619 - $1.1 Million
11,869 Added 10.93%
120,504 $9.99 Million
Q4 2017

Feb 14, 2018

BUY
$58.53 - $77.59 $84,107 - $111,496
1,437 Added 1.34%
108,635 $8.43 Million
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $31,276 - $39,954
652 Added 0.61%
107,198 $6.57 Million
Q2 2017

Aug 14, 2017

BUY
N/A
106,546
106,546 $4.9 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.